Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Strategies to manage hepatitis C virus (HCV) disease burden
Author: Wedemeyer, H
Duberg, AS
Buti, M
Rosenberg, WM
Frankova, S
Esmat, G
Ormeci, N
Van Vlierberghe, H
Gschwantler, M
Akarca, U
Aleman, S
Balik, I
Berg, T
Bihl, F
Bilodeau, M
Blasco, AJ
Mello, CEB
Bruggmann, P
Calinas, F
Calleja, JL
Cheinquer, H
Christensen, PB
Clausen, M
Coelho, HSM
Cornberg, M
Cramp, ME
Dore, GJ
Doss, W
El-Sayed, MH
Ergor, G
Estes, C
Falconer, K
Felix, J
Ferraz, MLG
Ferreira, PR
Garcia-Samaniego, J
Gerstoft, J
Giria, JA
Goncales, FL
Pessoa, MG
Hezode, C
Hindman, SJ
Hofer, H
Husa, P
Idilman, R
Kaberg, M
Kaita, KDE
Kautz, A
Kaymakoglu, S
Krajden, M
Krarup, H
Laleman, W
Lavanchy, D
Lazaro, P
Marinho, RT
Marotta, P
Mauss, S
Correa, MCM
Moreno, C
Mullhaupt, B
Myers, RP
Nemecek, V
Ovrehus, ALH
Parkes, J
Peltekian, KM
Ramji, A
Razavi, H
Reis, N
Roberts, SK
Roudot-Thoraval, F
Ryder, SD
Sarmento-Castro, R
Sarrazin, C
Semela, D
Sherman, M
Shiha, GE
Sperl, J
Starkel, P
Stauber, RE
Thompson, AJ
Urbanek, P
Van Damme, P
van Thiel, I
Vandijck, D
Vogel, W
Waked, I
Weis, N
Wiegand, J
Yosry, A
Zekry, A
Negro, F
Sievert, W
Gower, E
Abstract: The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
Subject: diagnosis
hepatitis C
disease burden
Country: EUA
Editor: Wiley-blackwell
Rights: fechado
Identifier DOI: 10.1111/jvh.12249
Date Issue: 2014
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.